Table 1.

Treatments before, during and after TNF antagonists

Before anti-TNF	During anti-TNF	After anti-TNF	Response to treatment
1 MMF, CYC	IFX, AZA	MTX (25 mg/w)	PR
2 MTX, CYC	IFX	CYC, AZA, RTX, CYC	PR
3 MTX (10 mg/w), plaquenil	IFX,MTX (20 mg/w)	MTX (25 mg/w), AZA (150 mg/d)	CR
4 MTX, CYC	IFX	CYC, AZA (200 mg/d)	CR
5 MTX (15 mg/w), plaquenil, thalidomide	IFX, MTX (10 mg/w),	MTX (20 mg/w), LEF (20 mg/d)	PR
6 MTX (20 mg/w), MMF, plaquenil (400 mg/d), thalidomide (150 mg/d)	IFX, MMF	MTX (20 mg/w), AZA (150 mg/d), LEF (20 mg/d)	PR
7 MMF (3 g/d), CYC, plaquenil	IFX	MMF (2 g/d), plaquenil, AZA (75 mg/d)	PR
8 CYC	IFX	CS	NR
9 MTX	ETN→IFX→ADA	MTX (15 mg/w)	NR

ADA, adalimumab; AZA, azathioprine; CS, corticosteroids; CYC, cyclophosphamide; ETN, etanercept; IFX, infliximab, LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; TNF, tumor necrosis factor; RTX, rituximab; CR: complete response; PR: partial response; NR : non-responder